Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma
Imaging Technology
OCTOBER 17, 2023
milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc., Adrenocortical carcinoma is a disease with a desperate need for new agents, as the last drug approved by the FDA was in 1970. Despite significant research efforts, the median survival of patients with metastatic disease is less than 15 months.
Let's personalize your content